A copy of this work was available on the public web and has been preserved in the Wayback Machine. The capture dates from 2020; you can also visit the original URL.
The file type is application/pdf
.
CRISPR-Cas, a robust gene-editing technology in the era of modern cancer immunotherapy
2020
Cancer Cell International
Cancer immunotherapy has been emerged as a promising strategy for treatment of a broad spectrum of malignancies ranging from hematological to solid tumors. One of the principal approaches of cancer immunotherapy is transfer of natural or engineered tumor-specific T-cells into patients, a so called "adoptive cell transfer", or ACT, process. Construction of allogeneic T-cells is dependent on the employment of a gene-editing tool to modify donor-extracted T-cells and prepare them to specifically
doi:10.1186/s12935-020-01546-8
pmid:32973401
pmcid:PMC7493839
fatcat:bjffwokrp5ew5borzuqventmxy